BioCryst Pharmaceuticals Quarterly Balance Sheet
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioCryst Pharmaceuticals financial position
As of Jun 30, 2026, BioCryst Pharmaceuticals reported total assets of $557.9 million, up 22.0% from a year earlier against total liabilities of $1.01 billion. Shareholders' equity was negative at -$454.3 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $155.0 million in cash and equivalents against $395.4 million of debt, a net debt position of $240.4 million.
The current ratio (current assets divided by current liabilities) was 2.32, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
BioCryst Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 154.97M | 171.59M | 89.74M | 84.08M | 88.03M | 105.19M | 104.71M | 96.84M | 78.41M | 84.33M | 110.64M | 150.91M |
| Short-Term Investments | 197.60M | 66.81M | 185.01M | 128.79M | 172.00M | 189.90M | 216.14M | 233.17M | 193.62M | 252.22M | 278.34M | 246.69M |
| Receivables | 110.76M | 109.27M | 106.82M | 91.33M | 91.18M | 93.39M | 79.07M | 72.46M | 68.76M | 60.59M | 56.95M | 53.65M |
| Inventory | 6.06M | 5.99M | 5.40M | 5.23M | 5.04M | 6.87M | 8.09M | 7.56M | 4.45M | 29.78M | 28.68M | 29.63M |
| Total Current Assets | 484.68M | 373.63M | 404.35M | 355.68M | 398.46M | 409.98M | 421.97M | 427.13M | 363.46M | 447.10M | 495.97M | 502.47M |
| Property, Plant & Equipment | 9.06M | 9.37M | 8.78M | 8.40M | 8.46M | 7.59M | 7.78M | 7.42M | 7.66M | 7.83M | 7.91M | 9.00M |
| Long-Term Investments | 0 | 20.57M | 61.16M | 39.67M | 10.10M | 20.55M | 20.32M | 19.43M | 64.32M | — | 0 | 0 |
| Total Assets | 557.85M | 465.05M | 514.16M | 446.42M | 457.19M | 480.05M | 490.42M | 491.25M | 472.42M | 467.89M | 516.96M | 522.92M |
| Accounts Payable | 11.46M | 10.96M | 15.83M | 5.57M | 8.59M | 10.05M | 11.64M | 13.48M | 7.79M | 11.91M | 20.89M | 10.57M |
| Total Current Liabilities | 208.85M | 195.39M | 196.07M | 190.24M | 177.16M | 139.85M | 160.38M | 153.57M | 129.06M | 119.92M | 149.99M | 90.76M |
| Long-Term Debt | 395.40M | 395.20M | 0 | 194.37M | 242.79M | 315.41M | 314.87M | 314.33M | 313.82M | 308.48M | 303.23M | 298.00M |
| Total Liabilities | 1.01B | 1.02B | 633.31M | 834.31M | 878.78M | 931.97M | 966.35M | 959.82M | 948.02M | 944.06M | 972.49M | 933.91M |
| Shareholders' Equity | -454.29M | -553.84M | -119.15M | -387.89M | -421.59M | -451.93M | -475.93M | -468.56M | -475.61M | -476.17M | -455.53M | -410.99M |
| Retained Earnings | -2.15B | -2.23B | -1.51B | -1.75B | -1.76B | -1.77B | -1.77B | -1.74B | -1.73B | -1.72B | -1.68B | -1.62B |
| Total Debt | 395.40M | 395.20M | 0 | 194.37M | 242.79M | 315.41M | 314.87M | 314.33M | 313.82M | 308.48M | 303.23M | 298.00M |
| Net Cash (Debt) | -42.83M | -156.80M | 274.75M | 18.51M | 17.24M | -20.32M | 5.98M | 15.68M | -41.80M | 28.07M | 85.76M | 99.59M |
| Shares Outstanding | 255.26M | 254.01M | 213.06M | 210.52M | 209.91M | 209.21M | 208.54M | 207.12M | 206.63M | 206.35M | 205.77M | 189.80M |
This table shows 12 quarterly periods of BioCryst Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BCRX's reporting calendar. What is a balance sheet?